Abstract library

69 results for "Maire".
#188 Carcinoid
Introduction: There is a serious need to develop a clear framework based on multidisciplinary team practice, in order to facilitate early detection and management of carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Assistant Prof Maria Derylo
#1169 Revalidation of QLQC30 and GINET21 Module in Patients with Neuroendocrine Tumors Using Online Questionnaire
Introduction: The GINET21 module measures PROMS for patients with NETs and was validated from 2006, since when there have been rapid changes in cancer therapeutics. Current module revalidation methodology a time and resource-intensive process, which may lag behind these treatment
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Dr Sebastian Kaupp-Roberts
Keywords: QoL PROM
#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases
Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Ron Basuroy
#1343 Management of Controversial Gastroenteropancreatic (GEP) Neuroendocrine Tumour (NET) Clinical Situations (CS) with Somatostatin Analogues (SSAs): Results of a Delphi Questionnaire (Q) Panel from the NETPraxis Program
Introduction: In NET CS where use of SSAs is controversial due to lack of evidence, clinical experience and expert opinion can help establish recommendations.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Isabel Sevilla
Keywords: SSA, Delphi, NETPraxis
#1696 On-going Evaluation of The Clinical Utility of the Health-Related Quality-Of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumours (NETs). QUALINETS Study
Introduction: Outcome measures reported by pts help to weigh benefit/effect of a therapy on quality of life (QoL), provided that their utility in clinical practice is proved. There are few QoL QNRs for pts with NETs, like QLQ-GINET21, with 21 items assessing muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr. Javier Gallego
#2146 Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz
Authors: Gallego J, Reig O, Sastre J, Garcia I, ...
#1407 Nutritional Status and Nutritional Risk in Patients with Neuroendocrine Tumors
Introduction: Malnutrition is common in patients with cancer and is associated with impaired function. No data are available on nutritional status (NS) and nutritional risk (NR) in patients with neuroendocrine tumors (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: PhD Gitte Dam
Authors: Borre M, Dam G, Knudsen A, Grønbæk H, ...
#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours
Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Zappa M, Rebours V, ...
Keywords: MGMT, Streptozotocin, PFS
#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?
Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Rachel van Leeuwaarde